SNUCPT

Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three asian populations

Kim EY, Cho DY, Shin HJ, Lee SS, Shon JH, Shin JG, Shin SG.

Clin Chim Acta 2008,Feb;388(1-2):68-72

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole

Kwon JS, Kim E, Kang DH, Choi JS, Yu KS, Jang IJ, Shin SG, Aplus Study Group.

Eur Neuropsychopharmacol 2008,Jan;18(12): 897-907

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients

Kim JR, Seo HB, Cho JY, Kang DH, Kim YK, Bahk YM, Yu KS, Shin SG, Kwon JS, Jang IJ.

Brit J Clin Pharmacol 2008,Jan;66(6): 802-810

Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects

Lim KS, Cho JY, Jang IJ, Kim BH, Kim JW, Jeon JY, Tae YM, Yi S, Eum SY, Shin SG, Yu KS.

Brit J Clin Pharmacol 2008,Jan;66(5): 660-666

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther 2008,Jan;30(10): 1817-1830

Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations

Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD.

Clin Pharmacol Ther 2008,Jan;84(3): 347-361

Effect of the CYP2C19 polymorphism on the eradication rate of helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage

Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, Song IS, Jung HC.

J Gastroenterol Hepatol 2008,Jan;23(8): 1287-1291

Safety, tolerability and pharmacokinetics of Udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects

Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, Cho JY, Yu KS, Shin SG, Paick JS, Jang IJ.

Brit J Clin Pharmacol 2008,Jan;65(6): 660-666

Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects

JY Chung, JY Cho, KS Yu, JR Kim, KS Lim, DR Sohn, SG Shin, and IJ Jang.

Clin Pharmacol Ther 2008,Jan;83(4): 595-600

Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers

Kim E, Kwon JS, Shin YW, Lee JS, Kang WJ, Jo HJ, Lee JM, Yu KS, Kang DH, Cho JY, Jang IJ, Shin SG.

Pharmacogenet Genomics 2008,Jan;18(2): 91-97

Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil

Lee HS, Park EJ, Ji HY, Kim SY, Im GJ, Lee SM, Jang IJ.

Xenobiotica 2008,Jan;38(1): 21-33